Puma Biotechnology Reports First Quarter 2026 Financial Results
Puma Biotechnology raised its full-year 2026 revenue and net income guidance, citing increased demand for NERLYNX, which is expected to result in a second consecutive year of demand growth. The company reported Q1 total revenue of $44.8 million and a net loss of $3.8 million, with R&D expenses increasing by $6.0 million year-over-year to support alisertib clinical trials.
Key figures
- Revenue
- 44800000
- Guidance
- FY2026 total revenue $222-$229 million, raised from $214-$221 million; net income $16-$19 million, raised from $10-$13 million
- Revenue Yoy
- -2.6%
- Total debt
- 0
- Rd expenses
- 19800000
- Cash and securities
- 101500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.